Have a feature idea you'd love to see implemented?
Let us know!
RARE Ultragenyx Pharmaceutical Inc
Price (delayed)
$54.82
Market cap
$5.05B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.22
Enterprise value
$4.61B
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of
Highlights
The quick ratio has soared by 53% QoQ and by 25% YoY
RARE's EPS is up by 29% year-on-year and by 9% since the previous quarter
Ultragenyx Pharmaceutical's debt has increased by 46% YoY but it has decreased by 8% from the previous quarter
The gross margin has decreased by 4.3% YoY
Key stats
What are the main financial stats of RARE
Market
Valuations
Earnings
Shares outstanding
92.17M
Market cap
$5.05B
Enterprise value
$4.61B
Price to earnings (P/E)
N/A
Price to book (P/B)
10.54
Price to sales (P/S)
9.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.58
Revenue
$481.3M
EBIT
-$586.86M
EBITDA
-$553.74M
Free cash flow
-$479.98M
Per share
Balance sheet
Liquidity
EPS
-$7.22
Free cash flow per share
-$5.54
Book value per share
$5.2
Revenue per share
$5.56
TBVPS
$16.26
Total assets
$1.62B
Total liabilities
$1.19B
Debt
$37.46M
Equity
$432.42M
Working capital
$691.77M
Debt to equity
0.09
Current ratio
3.54
Quick ratio
3.19
Net debt/EBITDA
0.8
Margins
Efficiency
Dividend
EBITDA margin
-115.1%
Gross margin
87.1%
Net margin
-121.6%
Operating margin
-114.1%
Return on assets
-41.4%
Return on equity
-266%
Return on invested capital
-76.8%
Return on capital employed
-43.6%
Return on sales
-121.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RARE stock price
How has the Ultragenyx Pharmaceutical stock price performed over time
Intraday
0.24%
1 week
-3.43%
1 month
-4.63%
1 year
70.35%
YTD
14.64%
QTD
-1.31%
Financial performance
How have Ultragenyx Pharmaceutical's revenue and profit performed over time
Revenue
$481.3M
Gross profit
$419.45M
Operating income
-$549.34M
Net income
-$585.12M
Gross margin
87.1%
Net margin
-121.6%
Ultragenyx Pharmaceutical's net margin has increased by 32% YoY and by 12% from the previous quarter
The company's operating margin rose by 32% YoY and by 13% QoQ
The revenue rose by 19% year-on-year and by 9% since the previous quarter
The operating income rose by 19% YoY and by 5% QoQ
Growth
What is Ultragenyx Pharmaceutical's growth rate over time
Valuation
What is Ultragenyx Pharmaceutical stock price valuation
P/E
N/A
P/B
10.54
P/S
9.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.58
RARE's EPS is up by 29% year-on-year and by 9% since the previous quarter
RARE's price to book (P/B) is 68% less than its last 4 quarters average of 32.5 and 21% less than its 5-year quarterly average of 13.3
The P/S is 36% lower than the 5-year quarterly average of 15.4 but 28% higher than the last 4 quarters average of 7.7
The revenue rose by 19% year-on-year and by 9% since the previous quarter
Efficiency
How efficient is Ultragenyx Pharmaceutical business performance
The ROE is up by 38% since the previous quarter but it is down by 8% year-on-year
RARE's return on sales is up by 31% year-on-year and by 12% since the previous quarter
The return on assets has increased by 16% year-on-year and by 10% since the previous quarter
The company's return on invested capital rose by 6% YoY
Dividends
What is RARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RARE.
Financial health
How did Ultragenyx Pharmaceutical financials performed over time
The total assets is 36% more than the total liabilities
The quick ratio has soared by 53% QoQ and by 25% YoY
The current ratio is up by 46% QoQ and by 23% YoY
Ultragenyx Pharmaceutical's debt is 91% less than its equity
Ultragenyx Pharmaceutical's debt to equity has plunged by 69% from the previous quarter and by 55% YoY
Ultragenyx Pharmaceutical's debt has increased by 46% YoY but it has decreased by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.